Anupam Rasayan completes Bliss GVS Pharma acquisition for ₹1,750 Cr

Anupam Rasayan India Ltd. has successfully concluded the acquisition of a 48.2% controlling stake in Bliss GVS Pharma Limited at ₹299 per share. This marks Anupam Rasayan's third strategic inorganic transaction, expanding its portfolio into finished dosage formulations. The acquisition, totaling approximately ₹1,750 crore, was funded through a combination of a ₹300 crore term loan and ₹1,450 crore from financial investors led by Bain Capital. Bliss GVS Pharma, a branded formulations company with over 150 brands and six internationally certified manufacturing facilities, will now be an integral part of Anupam Rasayan's expanding business. This move aims to build a diversified, integrated global pharmaceutical platform, leveraging synergies between Anupam Rasayan’s specialty chemicals expertise and Bliss GVS Pharma’s formulation capabilities. The combined platform, including previous acquisitions, is projected to achieve pro-forma revenue exceeding ₹4,000 crore and EBITDA of approximately ₹834 crore.